Arcturus Therapeutics Reports Q3 2026 Results with Narrowing Net Loss and Strong Cash Position
Arcturus Therapeutics (ARCT) reported third-quarter 2026 revenue of $18.3 million, up from $17.2 million in the prior year. This growth was primarily driven by a $12 million termination payment related to its collaboration with CSL Seqirus and the recognition of deferred revenue. The company successfully narrowed its net loss to $7.4 million ($0.26 per share) compared to a $13.4 million loss in the same period last year, aided by reduced research and development expenses. The company maintains a strong liquidity position with $184.8 million in cash as of September 30, 2026, providing a projected runway through the end of 2028. Key clinical milestones include the expected completion of Cohort 4 enrollment for its cystic fibrosis candidate (ARCT-032) by year-end 2026 and plans to present full Phase II data in Q2 2027. Additionally, Arcturus highlighted advancements in its LUNAR 2.0 delivery technology and the commercial distribution of KOSTAIVE in Japan.
Topics: clinical trial update cystic fibrosis earnings report net loss reduction revenue growth
Read the full article at Motley Fool
Part of the story Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026 (11 articles)